<DOC>
	<DOCNO>NCT02314481</DOCNO>
	<brief_summary>DARWIN II multi-arm non-randomised phase II trial , Eligible patient relapse NSCLC ( clinical trials.gov ref . NCT02183883 ) , The trial investigate ass intra-tumour heterogeneity ( clonal v subclonal actionable mutation ) associate PFS . Patients 1 ) without actionable mutation PDL1 positive 2 ) without actionable mutation PDL1 negative follow first line cytotoxic chemotherapy , receive MPDL3280A monoclonal antibody target anti-PDL1 . Patients BRAFV600 mutation , Her2 Amplification , ALK/RET gene rearrangement enrol arm treat vemurafenib , trastuzumab emtansine alectinib respectively . DARWIN II include extensive exploratory biomarker analysis investigate number genomic immune marker may predict response MPDL3280A help guide future clinical trial design .</brief_summary>
	<brief_title>Deciphering Antitumour Response Resistance With INtratumour Heterogeneity</brief_title>
	<detailed_description>DARWIN II exploratory phase II study examine role intra-tumour heterogeneity predict neo-antigens anti-tumour activity anti-PDL1 immunotherapy . It examine clonal dominance intratumour heterogeneity influence outcomes treatment , offer unique opportunity decipher mechanisms resistance immunotherapy anti-PDL1 . These data help improve future study design develop great understand patient selection immunotherapy patient NSCLC . The relationship intratumour heterogeneity cfDNA/CTCs also explore DARWIN II , may develop tool patient selection monitoring examine future study . Results DARWIN II help identify biomarker anti-PD-L1 therapy could use patient stratification future phase III trial molecule target T-cell inhibitory checkpoint . DARWIN II also provide preliminary data efficacy MPDL3280A , could use design randomised study . This multicentre non-randomised phase II study base patient relapse NSCLC , provide biopsy sample time relapse . The study arm : - Arm 1 : Patients either 1 ) without actionable mutation PDL1 positive 2 ) without actionable mutation PDL1 negative follow first line cytotoxic chemotherapy - MPDL3280A - Arm 2 : BRAFV600 - vemurafenib - Arm 3 : ALK/RET gene rearrangement - alectinib - Arm 4 : Her2 Amplification - trastuzumab emtansine</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Multiregion sequence data primary tumour available Subjects must willing biopsy relapse disease . Consent obtain TRACERx study . ( TRACERx patient ) use DARWIN2 trial entry biopsy consent form ( nonTRACERx patient ) . Procurement biopsy sample necessary time trial registration . However , patient must undergo biopsy prior commencement trial treatment . Arm1 : Absence actionable mutation PDL1 positive . OR Absence actionable mutation PDL1 negative follow first line cytotoxic chemotherapy Arm2 : Presence BRAFV600 mutation Arm3 : Presence ALK/RET gene fusion ALK IHC+/RET FISH Arm4 : Presence HER2 amplification HER2 IHC2+/3+ Absence sensitise EGFR mutation ( test accord local protocol ) . The exception patient progress DARWIN1 EGFR TKi offstudy ( agree follow prior discussion CI &amp; UCL CTC ) Written Informed consent DARWIN2 . ECOG PS 02 arm 13 , ECOG PS 01 arm 4 . No previous chemotherapy advance setting ( exception PDL1 negative receive first line cytotoxic chemotherapy ) Measurable disease RECIST v1.1 . See Appendix 4 At least 18 year age . Anticipated life expectancy least three month . Able swallow retain oral medication arm 2 &amp; 3 . Adequate organ function define follow baseline value : Absolute neutrophil count ( ANC ) ≥1.5x10^9/L Platelets ≥100x10^9/L Serum bilirubin ≤1.5 x upper limit normal ( ULN ) . ( In case Gilberts syndrome discus TMG ) Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) ≤3xULN ≤5x ULN liver metastasis present ) . Creatinine clearance must &gt; 30mL/min calculate measure . Women childbearing potential , men able father child , must willing practice acceptable method birth control trial 7 month end treatment . Women childbearing potential must negative pregnancy test within 14 day first dose trial medication . Suitable radical radiotherapy . Palliative radiotherapy within 1 week prior registration . Patients current preexist interstitial lung disease . Patients preexist autoimmune disease ( exception allow ) . Known hypersensitivity study IMP excipients Inability understand comply requirement trial , trial protocol provide inform consent . Anticancer therapy include chemotherapy , radiation therapy , immunotherapy , biologic therapy , major surgery within 14 day prior registration . Treatment systemic corticosteroid systemic immunosuppressive medication ( include limit prednisone , dexamethasone , cyclophosphamide , azathioprine , methotrexate , thalidomide , anti−tumor necrosis factor ( TNF ) agent ) within 2 week prior registration , anticipated requirement systemic immunosuppressive medication trial ( Patients receive acute , lowdose , systemic immunosuppressant medication ( e.g. , onetime dose dexamethasone nausea ) may enrol trial discussion CTC . The use inhale corticosteroid mineralocorticoid ( e.g. , fludrocortisone ) allow . Lowdose supplemental corticosteroid adrenocortical insufficiency allow ) . Known human immunodeficiency virus ( HIV ) , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) syphilis infection . Subjects evidence hepatitis B virus clearance may enrol . History malignancy ; Exception : ( ) Subjects successfully treat diseasefree 3 year , ( b ) history completely resect nonmelanoma skin cancer , ( c ) successfully treat situ carcinoma , ( ) CLL stable remission , ( e ) indolent prostate cancer require antihormonal therapy histologically confirm tumour lesion clearly differentiate lung cancer target nontarget lesion eligible . Patients symptomatic brain metastasis . The following cardiac abnormality : Corrected QT ( QTc ) interval ≥480 msec Arm 4 : LVEF &lt; 50 % History acute coronary syndrome ( include unstable angina ) within past 6 month Coronary angioplasty , stenting within past 24 week Class III , IV heart failure define New York Heart Association ( NYHA ) functional classification system History know arrhythmia ( except sinus arrhythmia ) within past 6 month History myocardial infarction within past 6 month Patients take medicine know prolong QT interval 2 week prior registration . Use also permit trial Arm 3 Use potent inhibitor inducer CYP3A , 2 week 5 halflives ( whichever longer ) prior registration . Use also permit trial . Uncontrolled medical condition ( i.e. , diabetes mellitus , hypertension , uncorrectable electrolyte abnormality ( include magnesium etc ) , psychological , familial , sociological , geographical condition permit compliance protocol ; unwillingness inability follow procedure require protocol . Pregnant , lactate actively breastfeed female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>Clonal dominance</keyword>
	<keyword>Clonal evolution</keyword>
	<keyword>Intratumour heterogeneity</keyword>
	<keyword>Genomic instability</keyword>
	<keyword>Drug resistance</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>PDL1</keyword>
	<keyword>BRAF V600</keyword>
	<keyword>ALK</keyword>
	<keyword>RET</keyword>
	<keyword>HER2 amplification</keyword>
	<keyword>MPDL3280A</keyword>
	<keyword>Vemurafenib</keyword>
	<keyword>Alectinib</keyword>
	<keyword>T-DM1</keyword>
	<keyword>Trastuzumab emtansine</keyword>
	<keyword>TRACERX</keyword>
</DOC>